Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Towa Pharmaceutical Enter Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Rivastigmine Multi-Day Transdermal Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Myung in Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Zambon Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"D","amount":"$33.9 million","upfrontCash":"$10.9 million","newsHeadline":"Luye Pharma Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal Patches on China\u2019s Mainland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Exeltis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Exeltis Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daehwa Pharm Applies for Approval of Anti-Dementia Patch in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Application for Luye Pharma's Rivastigmine Multi-Day Transdermal Patch Product Rivalif\u00ae under Review at EU Competent Authorities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Transdermal Patch Launches in China Bringing Benefits to the Country\u2019s 9 Million Alzheimer\u2019s Patients and Their Families","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019s Innovative Alzheimer\u2019s Disease Therapy Rivastigmine Multi-Day Transdermal Patch Now Eligible for Marketing Authorization in Several EU Countries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019s Innovative Alzheimer\u2019s Disease Therapy Rivastigmine Multi-Day Transdermal Patch Receives Marketing Approval in the UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Application for Luye Pharma\u2019s Rivastigmine Twice Weekly Transdermal Patch Accepted in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Rivastigmine

    Menu

    Rivastigmine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Luye Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma Grants Myung in Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea

              Details:

              The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for the treatment of mild to moderate dementia associated with Alzheimer's disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivalif

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Myung In Pharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership February 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease

              Details:

              Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivastigmine MD

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Gensci

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Daehwa Pharmaceutical Co. Ltd

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Daehwa Pharm Applies for Approval of Anti-Dementia Patch in China

              Details:

              Rivastigmine patch is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Knight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

              Details:

              Exelon Patch (rivastigmine transdermal system) is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Exelon

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Marketing Authorization Application for Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Accepted in China

              Details:

              Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivastigmine MD

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Gensci

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma Grants Exeltis Exclusive Commercialization Rights to its Innovative Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Polan...

              Details:

              Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivastigmine MD

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Exeltis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal Patches on China’s Mainland

              Details:

              Through the agreement, the company grants Gensci exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivastigmine MD

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Gensci

              Deal Size: $33.9 million Upfront Cash: $10.9 million

              Deal Type: Agreement December 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma Grants Zambon Exclusive Commercialization Rights to its Innovative Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland

              Details:

              Through the agreement, the company grants Zambon exclusive rights to commercialize Rivalif (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivalif

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Zambon Group SpA

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma’s Innovative Alzheimer’s Disease Therapy Rivastigmine Multi-Day Transdermal Patch Receives Marketing Approval in the UK

              Details:

              Zeyzelf (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Zeyzelf

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Luye Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma’s Innovative Alzheimer’s Disease Therapy Rivastigmine Multi-Day Transdermal Patch Now Eligible for Marketing Authorization in Several EU Countries

              Details:

              Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivalif

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Interquim Rivastigmine New
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY